Your browser doesn't support javascript.
Antibody therapy for COVID-19.
Hammarström, Lennart; Marcotte, Harold; Piralla, Antonio; Baldanti, Fausto; Pan-Hammarström, Qiang.
  • Hammarström L; Department of Biosciences and Nutrition, NEO, Karolinska Institutet, Huddinge.
  • Marcotte H; Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden.
  • Piralla A; Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo.
  • Baldanti F; Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo.
  • Pan-Hammarström Q; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Curr Opin Allergy Clin Immunol ; 21(6): 553-558, 2021 12 01.
Article in English | MEDLINE | ID: covidwho-2161180
ABSTRACT
PURPOSE OF REVIEW To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period. RECENT

FINDINGS:

Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results.

SUMMARY:

Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Curr Opin Allergy Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Curr Opin Allergy Clin Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article